Molecular pathology and genetics of gastrointestinal neuroendocrine tumours

@article{Lewis2014MolecularPA,
  title={Molecular pathology and genetics of gastrointestinal neuroendocrine tumours},
  author={Mark A Lewis and James C Yao},
  journal={Current Opinion in Endocrinology \& Diabetes and Obesity},
  year={2014},
  volume={21},
  pages={22–27}
}
  • Mark A Lewis, James C Yao
  • Published 1 February 2014
  • Biology, Medicine
  • Current Opinion in Endocrinology & Diabetes and Obesity
Purpose of reviewNeuroendocrine tumours (NETs) of the luminal gastrointestinal tract and pancreas are increasing in incidence and prevalence. Prior assumptions about the benign nature of ‘carcinoids’ and the clinical importance of distinguishing functional vs. nonfunctional tumours are being overturned through greater understanding of disease behaviour and heterogeneity. This review highlights the most contemporary genetic and molecular insights into gastroenteropancreatic NETs. Recent… 
Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
Neuroendocrine Neoplasms of the Stomach
TLDR
The treatment of advanced G-NETs needs to be multimodal and best accomplished in subspecialty referral centers with advanced clinical, pathologic, and imaging expertise, in order to succeed with more personalized patient management strategies.
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract
TLDR
The role of miRNAs in GEP-NET carcinogenesis and their possible use as novel diagnostic, prognostic and predictive biomarkers are summarized.
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
TLDR
Significant molecular differences were observed in GEP-NENs by tumor location and grade, indicating differences in carcinogenic pathways and biology.
An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis
TLDR
An assessment of all published data indicated that CgA does not exhibit the minimum required metrics to function as a clinically useful biomarker for lung NENs, and exhibits major limitations as an effective and accurate biomarkers for either PC or SCLC.
Neuroendocrine Tumor Biomarkers: Current Status and Perspectives
TLDR
Limits in current practice are examined and contemporary viable strategies under evaluation are described, including the identification of novel analytes (gene transcripts, microRNA, circulating tumor cells and metabolic imaging agents that identify disease.
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
TLDR
It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy and a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic effectiveness.
Consensus on biomarkers for neuroendocrine tumour disease.
The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract
TLDR
This study demonstrates that a blood-based multianalyte NET gene transcript measurement of well-differentiated small intestinal and pancreatic neuroendocrine tumor disease is sensitive and specific and outperforms the current monoanalyte diagnostic strategy of plasma CgA measurement.
...
1
2
3
...

References

SHOWING 1-10 OF 44 REFERENCES
The molecular genetics of gastroenteropancreatic neuroendocrine tumors
TLDR
Divergence in gene expression patterns in the development of GI carcinoids and PETs was identified, whereas examination of the PET and GI carcinoid data demonstrated only few areas of overlap in the accumulation of genetic aberrations, which suggest that the recent World Health Organization classification of GEP‐NETs may require updating.
Neuroendocrine tumor disease: an evolving landscape.
TLDR
There is a place for streptozotocin, temozolomide, and capecitabine in the management of pancreatic NENs, while new agents targeting either mTOR or angiogenic pathways have shown efficacy in these lesions.
The genomic landscape of small intestine neuroendocrine tumors.
TLDR
Sequencing-based analysis may provide provisional grouping of SI-NETs by therapeutic targets or deregulated pathways, and identified recurrently altered mechanisms of carcinogenesis: chromatin remodeling, DNA damage, apoptosis, RAS signaling, and axon guidance.
Notch 1 tumor expression is lacking in highly proliferative pancreatic neuroendocrine tumors
TLDR
No correlation between Notch1 expression and clinical data was found, and the missing Notch expression in the malignant tumor course might be used as a potential predictive marker, but further studies are needed to investigate the underlying molecular mechanism.
The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant
TLDR
The consideration of NENs as functional or nonfunctional is an archaic clinical concept that should be discarded since the tumors are indistinguishable at a cellular, biological, and morphological level.
Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene
TLDR
ATM down-regulation was strongly associated with metastatic NETs when compared with non-metastaticNETs and ATM may be a potential predictive marker for metastasis as well as a novel target in metastatic GEP-NETs.
Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.
TLDR
This review will present the most widely used systems for classifying, grading, and staging NETs and will summarize the recommendations for the data to be included in standard pathology reports of these uncommon tumors.
The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood
TLDR
A panel of 51 marker genes differentiates NENs from controls with a high PPV and NPV (>90%), identifies pancreatic and gastrointestinal N ENs with similar efficacy, and confirms GEP-NENs when CgA levels are low.
Pathology - grading and staging of GEP-NETs.
Chromosome 3p alterations in pancreatic endocrine neoplasia
TLDR
Ch Chromosome 3p copy number alterations are frequent events in advanced stage PET, with gains prevailing in PDEC while losses are more frequent in WDEC, supporting the view that a specific pattern of alterations are involved in these diverse disease subtypes.
...
1
2
3
4
5
...